Qi Yue is a Registered Foreign Lawyer (New York) in Hong Kong and a partner of Gibson, Dunn & Crutcher LLP. He is a member of the firm’s Corporate, Mergers and Acquisitions, and Private Equity Practice Groups. Qi has extensive experience in China-related public and private M&A and Private Equity transactions, including complex cross-border mergers and acquisitions, business combinations and carve-outs, strategic and private equity buyouts, minority investments and venture capital transactions, offshore and onshore joint ventures and other strategic cooperation. He has also represented diverse participants in going private transactions involving Chinese companies listed in the United States, including special committees, buyer consortiums, founders, co-investors and other financing sources.

Qi was named by The Legal 500 Asia Pacific 2023 for Corporate and M&A in China, by China Business Law Journal as a Rising Star in 2022 which identifies 20 prominent up-and-coming foreign firm lawyers for China-related business, by IFLR1000 as a Rising Star Partner in 2022, and by Asian Legal Business in its 2021 China Top 15 Rising Lawyers list which showcases the most accomplished lawyers in China under the age of 40. His work in CPE’s sale of a majority stake in Acotec, a Chinese medical technology company publicly listed in Hong Kong, to Boston Scientific was nominated as a finalist in the M&A Deal of the Year by ALB China Law Awards 2023.

His private equity, asset management and sovereign wealth funds clients include Advent International, Affinity Equity Partners, AGIC Capital, Anchor Equity, Apax Partners, Blackstone Real Estate Partners, Canada Pension Plan Investment Board, CITIC Capital, CPE, CITIC Securities Investment, Davidson Kempner Asia, Goldman Sachs, Hillhouse Capital, I Squared Capital, JPMorgan Asset Management, KKR, Kuwait Investment Authority, Macquarie, Primavera Capital and Silver Lake Partners, among others.

Qi has worked on a number of landmark transactions. His recent and most significant experience includes advising:

• CPE in its sale of a majority stake in Acotec, a Chinese medical technology company publicly listed in Hong Kong, to Boston Scientific, through a US$520 million partial offer
• CPE in the US$4.8 billion going private transaction of China Biologic Products Holdings
• The Special Committee of Sina Corporation in the Company’s US$2.6 billion going private transaction
• NetEase in the sale of its cross-border e-commerce platform Kaola to Alibaba for US$2 billion
• Beijing NAURA Technology in the acquisition of Akrion Systems, a leading supplier of advanced wafer surface preparation solutions in the U.S.
• Tsinghua Unigroup in the acquisition of a majority stake in Hewlett-Packard’s China-based server, storage and technology services businesses for US$2.5 billion and the related joint venture
• Danone in the formation of chilled yogurt joint ventures with Mengniu and the strategic investment in Mengniu’s Hong Kong Listco for approximately US$420 million

Prior to joining Gibson Dunn in 2015, Qi worked at Simpson Thacher & Bartlett LLP where he spent two years in their New York office and three years in their Beijing office. Qi received his Juris Doctor from Harvard Law School in 2010, his Master of Science from the University of Washington in 2007 and his Bachelor of Science from Peking University in 2002. He is admitted to practice in the state of New York and is fluent in Mandarin and English.